NORMAN SCHWARTZ: Open Payments
NPI 1255322335 · PATASKALA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 24 payments from 12 companies in 2025. Trend: 2023 $787 · 2024 $363 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 6 | $109 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $63 |
| Lundbeck LLC | 3 | $53 |
| ABBVIE INC. | 2 | $34 |
| Abbott Laboratories | 2 | $34 |
| Indivior Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Merck Sharp & Dohme LLC | 1 | $15 |
Products named: GEMTESA, KEVEYIS, CAPLYTA, REXULTI, VRAYLAR, FREESTYLE LIBRE 3, SUBLOCADE, KISUNLA.
Industry payments across OH — which companies pay providers there.
